Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Strategic Diagnostics (SDI), a provider of biotechnology-based products and services, has been selected again by Science Applications International Corporation - Frederick (SAIC-F), to develop monoclonal antibodies for the National Cancer Institute’s 'Clinical Proteomic Technologies for Cancer' initiative.
Subscribe to our email newsletter
SDI was selected for a third consecutive time as the key monoclonal antibody provider. The National Cancer Institute’s CPTC will extensively characterize these reagents, consistent with their mission to make available high-quality reagents with baseline data, to research scientists.
Fran DiNuzzo, president and CEO of SDI, said: “SDI is proud to be a key supplier to this important large-scale cancer research initiative. Being selected for a third consecutive year by SAIC-F underscores our belief that SDI’s expertise, quality, infrastructure, and capacity position us as a premier supplier of comprehensive antibody services.
“Moreover, as the study of proteins continues to increase in importance to the research community, and antibodies continue to be the most widely-used tools for understanding the molecular dynamics underlying disease, we anticipate a continued demand for SDI products and services.”